Clinical & Pharmaceutical Solutions through Analysis
October 5 - 8, 2015
Sheraton Bucks County Hotel, Langhorne, PA
Where Technology and Solutions Meet!
CPSA USA 2015
Getting Medicines to Patients Faster by Eliminating the Bottlenecks in Drug Discovery and Development
The Distinguished Lecture Series
Hosted by SCIEX
Each year, The Distinguished Lecture Series welcomes innovative and cutting edge lecturers to encourage discussion, exchange of ideas as well as collaboration.
The Distinguished Lecture Series event takes place Monday evening
CPSA 2015 Distinguised Lecturer
Fetal Alcohol Exposure - A 30 Year Search for a Reliable Biomarker
Douglas Lewis is the founder, president and scientific director of United States Drug Testing Laboratories, Inc. (USDTL) where he oversees development of new matrices for use in diagnosing substances of abuse, such as: umbilical cord tissue used to determine substance exposure in newborns, and fingernails to determine alcohol biomarkers and substances of abuse.
Lewis’s research record includes co-principal investigator on a $6.57 million NIDA funded grant entitled "Prenatal Methamphetamine Exposure and Child Outcome," co-investigator on three Small Business Innovation Research (SBIR) Phase I grants—“Diagnostic Viability of Umbilical Cord Specimens,” “Using Human Hair to Determine Long Term Alcohol Abuse” and Hair Ethyl Glucuronide as a Long-Term Alcohol Biomarker”—and co-investigator on an SBIR Phase II grant “Diagnostic Viability of Umbilical Cord Specimens.
Prior to USDTL, he spent five years in academia as an assistant professor of clinical pathology at Northwestern University Medical School while also serving as the head of the toxicology section at the Children’s Memorial Hospital in Chicago. During his tenure at Northwestern and Children’s, Lewis established the first non-Olympic anabolic steroids testing laboratory in the United States and was a toxicologist for the U.S. Weight Lifting Federation
Distinguished Lecturers Past